{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"10","value":"1.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Study Schema: Bortezomib will be administered on Days 1. 4, 8, and 11. Response will be assessed subsequent to each 21-day cycle. Progression is defined using the Bladé criteria, defined progression as an increase of \\>25% in paraprotein or urinary light chain excretion (or marrow plasma cell percentage in the marrow","dispersionType":"Full Range","groups":[{"description":"Bortezomib will be administered at 1.3 mglm2 IVP on Days 1. 4, 8, and 11. Response will be assessed subsequent to each cycle. A total of 8 cycles would beplanned. Patients would be removed subsequent to Cycle 2. if progression of disease is documented.","id":"OG000","title":"Bortezomib and Bevacizumab"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"18 months","title":"Median Number of Cycles to Tumor Progression (TTP)","type":"PRIMARY","unitOfMeasure":"Cycles Prior to Tumor Progression"}